Literature DB >> 25738264

Testosterone enhances lipopolysaccharide-induced interleukin-6 and macrophage chemotactic protein-1 expression by activating the extracellular signal-regulated kinase 1/2/nuclear factor-κB signalling pathways in 3T3-L1 adipocytes.

Chunlin Su1, Min Chen2, Haiyan Huang3, Jinfang Lin1.   

Abstract

Low-grade chronic inflammation is commonly found in patients with polycystic ovary syndrome (PCOS) who exhibit hyperandrogenism or hyperandrogenemia. Clinical studies have shown that hyperandrogenemia is closely correlated with low-grade chronic inflammation. However, the mechanism underlying this correlation remains unclear. Recent studies have suggested that adipocytes increase the production of proinflammatory mediators such as interleukin-6 (IL-6) and macrophage chemotactic protein-1 (MCP-1) when the inflammatory signal transduction cascade system is activated by external stimuli. The present study aimed to evaluate the effects of testosterone on the innate signalling and expression of proinflammatory mediators in 3T3-L1 adipocytes, which were or were not induced by lipopolysaccharide (LPS). The effects of testosterone on the expression of proinflammatory mediators, nuclear factor-κB (NF-κB), and extracellular signal-regulated kinase 1/2 (ERK1/2) signalling pathways were investigated using an enzyme-linked immunosorbent assay, reverse transcriptase-polymerase chain reaction, western blot analysis and an electrophoresis mobility shift assay. Testosterone induces IL-6 and MCP-1, and enhances LPS-induction of IL-6 and MCP-1. However, the effects are not simply additive, testosterone significantly enhanced the effects of LPS-induced inflammation factors. Testosterone induces the phosphorylation of ERK1/2 and NF-κB. The effect of testosterone on the expression of IL-6 and MCP-1 is inhibited by PD98059 , an ERK1/2 inhibitor, and PDTC, an NF-κB inhibitor. The results indicate that testosterone enhances LPS-induced IL-6 and MCP-1 expression by activating the ERK1/2/NF-κB signalling pathways in 3T3-L1 adipocytes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25738264     DOI: 10.3892/mmr.2015.3401

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Prediction of Gut Microbial Community Structure and Function in Polycystic Ovary Syndrome With High Low-Density Lipoprotein Cholesterol.

Authors:  Xuping Zhu; Yanyu Li; Yanmin Jiang; Jisheng Zhang; Ru Duan; Lin Liu; Chao Liu; Xiang Xu; Lu Yu; Qian Wang; Fan Xiong; Chengming Ni; Lan Xu; Qing He
Journal:  Front Cell Infect Microbiol       Date:  2021-07-19       Impact factor: 5.293

2.  Advanced glycation end products decrease collagen I levels in fibroblasts from the vaginal wall of patients with POP via the RAGE, MAPK and NF-κB pathways.

Authors:  Yi-Song Chen; Xiao-Juan Wang; Weiwei Feng; Ke-Qin Hua
Journal:  Int J Mol Med       Date:  2017-08-11       Impact factor: 4.101

3.  Exploration of the Relationship Between Gut Microbiota and Polycystic Ovary Syndrome (PCOS): a Review.

Authors:  Xiaoxuan Zhao; Yuepeng Jiang; Hongyan Xi; Lu Chen; Xiaoling Feng
Journal:  Geburtshilfe Frauenheilkd       Date:  2020-02-21       Impact factor: 2.915

4.  Metabolic and hormonal effects of melatonin and/or magnesium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Mohammad Alizadeh; Majid Karandish; Mohammad Asghari Jafarabadi; Lida Heidari; Roshan Nikbakht; Hossein Babaahmadi Rezaei; Reihaneh Mousavi
Journal:  Nutr Metab (Lond)       Date:  2021-06-06       Impact factor: 4.169

5.  Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment.

Authors:  Alison E Obr; Sushil Kumar; Yun-Juan Chang; Joseph J Bulatowicz; Betsy J Barnes; Raymond B Birge; Deborah A Lazzarino; Emily Gallagher; Derek LeRoith; Teresa L Wood
Journal:  Breast Cancer Res       Date:  2018-11-20       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.